Xbiotech inc.XBIT.US Overview
XBIT Overall Performance
XBIT AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
XBIT Current Performance
0.31%
Xbiotech inc.
-1.93%
Avg of Sector
-0.59%
S&P500
XBIT Key Information
XBIT Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
XBIT Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
XBIT Profile
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Price of XBIT
XBIT FAQ
When is XBIT's latest earnings report released?
The most recent financial report for Xbiotech inc. (XBIT) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XBIT's short-term business performance and financial health. For the latest updates on XBIT's earnings releases, visit this page regularly.
How much cash does XBIT have?
At the end of the period, Xbiotech inc. (XBIT) held Total Cash and Cash Equivalents of 152.94M, accounting for 0.86 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is XBIT's EPS continuing to grow?
According to the past four quarterly reports, Xbiotech inc. (XBIT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of XBIT?
Xbiotech inc. (XBIT)'s Free Cash Flow (FCF) for the period is -6.04M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 49.68% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.